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Abstract
Introduction Preoperative hemodilution is an established
practice that is applied to reduce surgical blood loss. It has been
proposed that polyethylene glycol (PEG) surface decorated
proteins such as PEG-conjugated human serum albumin may be
used as non-oxygen-carrying plasma expanders. The purpose of
this study was to determine whether there is any difference in
survival time after severe hemorrhagic shock following extreme
hemodilution using a conventional hydroxyethyl starch (HES)-
based plasma expander or PEG-albumin.
Methods Experiments were performed using the hamster
skinfold window preparation. Human serum albumin that was
surface decorated with PEG was compared with Voluven 6%
(Fresenius Kabi, Austria; a starch solution that is of low
molecular weight and has a low degree of substitution; HES).
These plasma expanders were used for a 50% (blood volume)
exchange transfusion to simulate preoperative hemodilution.
Exchange transfusion was followed by a 60% (blood volume)
hemorrhage to reproduce a severe surgical bleed over a 1 hour
period. Observation of the animal was continued for another
hour during the shock phase.
Results The PEG-albumin group exhibited significantly greater
survival rate than did the HES group, in which none of the
animals survived the hemorrhage phase of the experiment.
Among the treatment groups there were no changes in mean
arterial pressure and heart rate from baseline after hemodilution.
Both groups experienced gradual increases in arterial oxygen
tension and disturbance in acid-base balance, but this response
was more pronounced in the HES group during the shock
period. Mean arterial pressure remained elevated after the initial
hemorrhage period in the PEG-albumin group but not in the
HES group. Maintenance of a greater mean arterial pressure
during the initial stages of hemorrhage is proposed to be in part
due to the improved volume expansion with PEG-albumin, as
indicated by the significant decrease in systemic hematocrit
compared with the HES group. PEG-albumin treatment yielded
higher functional capillary density during the initial stages of
hemorrhage as compared with HES treatment.
Conclusion The ability of PEG-albumin to prolong maintenance
of microvascular function better than HES is a finding that would
be significant in a clinical setting involving preoperative blood
management and extreme blood loss.
Introduction
Preoperative blood management techniques are increasingly
being standardized, with the aim being to limit allogenic blood
transfusions in elective surgery [1,2]. Surgical patients who
are managed in accordance with bloodless or limited blood
usage standards are hemodiluted with a colloid solution
before surgery in order to salvage autologous blood for later
use. This procedure results in a moderate reduction in hemat-
ocrit but, because of compensatory increases in cardiac out-
put, there is no adverse effect on oxygen delivery [3]. The
success of this procedure significantly depends on achieving
and maintaining normovolemic status.
BV = blood volume; FCD = functional capillary density; HAS = human serum albumin; HES = hydroxyethyl starch; HR = heart rate; MAP = mean 
arterial blood pressure; PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; PEG = polyethylene glycol; RBC = red blood cell; TBV 
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Conventional colloids such as dextrans, gelatins, hydroxyethyl
starch (HES), and albumin have been used for blood volume
replacement therapy and have become well established for
preoperative volume substitution [4,5]. However, which colloid
to use remains a point of contention because, in addition to
their intravascular volume expansion properties, most of these
materials also have a variable influence on other factors such
as coagulation and renal function.
Colloids provide lasting circulating volume expansion because
of their oncotic properties and slow clearance rate from the
circulation [6,7]. HES, a natural polymer of amylopectin, has a
molecular structure that allows for a variety of chemical modi-
fications, which result in different degrees of volume expansion
and half-life properties, depending on the degree of substitu-
tion or hydroxylation, molecular weight and concentration
[4,5].
It has been proposed that polyethylene glycol (PEG) surface
decorated proteins such as PEG-conjugated human serum
albumin [8] and hemoglobin [9,10] may represent new types
of plasma expander: non-oxygen-carrying and oxygen-carrying,
respectively. PEGylation of these proteins yields oncotic prop-
erties similar to those of the natural protein but at much lower
concentrations. Therefore, less PEG-albumin is needed to
attain the same oncotic effect as its counterpart protein. Ani-
mal studies provide evidence that PEG-albumin (carrying six
copies of PEG-5,000 chains per molecule), at concentrations
of 4 g albumin/dl, is an effective plasma expander during
hemodilution [11,12] and resuscitation fluid for use in hemor-
rhagic shock [13]. At concentrations as low as 2.5 g albumin/
dl, PEG-albumin (carrying 10 copies of PEG-5,000 chains per
molecule) is better able to resuscitate from induced endotox-
emia, thus preventing the development of circulatory collapse,
as compared with 6 g/dl dextran 70 (molecular weight 70 kDa)
[14]. PEG-albumin has the advantages of a longer half-life
because of reduced glomerular filtration and diminished prote-
olysis [15,16]. Additionally, PEGylation reduces the potential
immunologic activity [17] and drug-binding capacity [18] of
albumin. In the present study we use a new type of PEG-albu-
min, in which human serum albumin (HSA) is surface deco-
rated with about six PEG-5,000 chains through extension arm
facilitated PEGylation. This new type of molecule could be
suitable as a plasma expander, which is effective at reduced
plasma concentrations and potentially has a better defined
pharmacokinetic profile because of its uniform molecular size.
A critical component of blood volume replacement fluids is
their plasma expansion properties, and how these properties
promote the maintenance of systemic and microvascular func-
tion during extreme blood volume challenges. In this study we
tested the functionality of PEG-albumin used experimentally in
preoperative hemodilution (50% blood volume) followed by a
significant surgical bleed (60% exponential bleed). Investiga-
tions were conducted at the microvascular level in the hamster
window chamber model hemodiluted with Voluven (Fresenius
Kabi, Graz, Austria; HES). Results were compared with PEG-
albumin using the same protocol. The objective was to deter-
mine the relative merits of these colloids as preoperative
hemodilution plasma expanders, and to determine whether
there was any effect on survival time and maintenance of
microvascular perfusion after 1 hour of hemorrhage.
Materials and methods
Animal preparation
Investigations were conducted in male golden Syrian ham-
sters weighing 50 to 65 g (Charles River Laboratories, Bos-
ton, MA, USA). Animal handling and care were provided
following the procedures outlined in the Guide for the Care
and Use of Laboratory Animals (US National Research Coun-
cil, 1996). The local Animal Subjects Committee approved the
study. The hamster window chamber model is widely used for
microvascular studies in the unanesthetized state, and the
complete surgical technique for the preparation has previously
been described in detail [19,20]. The animal was allowed at
least 2 days for recovery; its chamber was then assessed
under the microscope for any signs of edema, bleeding, or
unusual neovascularization. Barring these complications, the
animal was anesthetized again with pentobarbital sodium.
Arterial and venous catheters (polyethylene-50) were
implanted in the carotid artery and jugular vein, respectively.
Catheters were tunneled under the skin and exteriorized at the
dorsal side of the neck, where they were attached to the cham-
ber frame with tape. This model allows the study of an intact
subcutaneous tissue and a single thin retractor muscle free
from surgical manipulation and exposure to ambient atmos-
pheric conditions.
Inclusion criteria
Animals were deemed suitable for the experiments if the fol-
lowing were satisfied: systemic parameters were within normal
range, namely heart rate (HR) above 320 beats/minute, mean
arterial blood pressure (MAP) above 80 mmHg, systemic
hematocrit above 45%, and arterial oxygen tension (PaO2)
above 50 mmHg; and microscopic examination of the tissue
under high magnification (40 × objective; NA [numerical aper-
ture] 0.7 SW [salt water]; Olympus, Central Valley, PA, USA)
did not reveal signs of edema or bleeding.
Systemic parameters
MAP and HR were monitored continuously (MP 150; Biopac
Systems, Inc., Santa Barbara, CA, USA), except when the
catheters were used to take samples for laboratory parame-
ters. Arterial blood samples taken in heparinized microcapillary
tubes (40 μl) were centrifuged to determine hematocrit.
Blood chemistry
Arterial blood was collected in heparinized glass capillaries
(0.05 ml) from the carotid catheter and immediately analyzed
for PaO2, arterial carbon dioxide tension (PaCO2), and pHAvailable online http://ccforum.com/content/12/2/R54
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(Blood Chemistry Analyzer 248; Bayer, Norwood, MA, ASA).
The comparatively low PaO2 and high PaCO2 of these animals
was a consequence of their adaptation to a fossorial
environment.
Microhemodynamics
Arteriolar and venular blood flow center line velocities were
measured online using the photodiode cross-correlation
method [21] (Photo Diode/Velocity Tracker 102B; Vista Elec-
tronics, San Diego, CA, USA). Measured centerline velocity
(V) was corrected according to vessel size to obtain mean red
blood cell (RBC) velocity from centerline velocity measure-
ments [22]. Video image shearing was used to measure vessel
diameter (D; Image Shearing Monitor; Vista Electronics, San
Diego, CA, USA) [23]. Blood flow (Q) was calculated as Q =
V × π (D/2)2. Changes in arteriolar and venular diameter from
baseline were used as indicators of changes in vascular tone.
Functional capillary density
Capillaries were considered functional if RBC transit was
observed through the capillary segments during a 30-second
period. Functional capillary density (FCD) was tabulated from
capillary lengths with RBC transit in an area comprised of 20
successive microscopic fields under 40× magnification. FCD
(cm-1) is the total length of RBC-perfused capillaries divided
by the surface area.
Experimental design
The unanesthetized animal was placed into a restraining tube
for the duration of the experiment. The tube containing the
conscious animal was fixed to the microscope stage of an
intravital microscope (BX51 W1, 40× objective, NA 0.7 SW;
Olympus). The tissue image was projected onto a CCD cam-
era (4815-2000; COHU, San Diego, CA, USA) connected to
a timer and viewed on a closed circuit monitor. Arterioles and
venules, chosen by their visual acuity (three to seven of each
type), were characterized by their blood flow, velocity and
diameter. FCD was assessed. Vessels chosen for baseline
observations were followed throughout the experiment to elim-
inate bias. Animals were allowed 30 minutes to adjust to the
tube environment before measuring baseline parameters
(MAP, HR, arterial blood gases and pH, and systemic
hematocrit).
Isovolemic hemodilution
An isovolemic hemodilution of 50% blood volume (BV; esti-
mated as 7% of body weight) was performed by simultaneous
withdrawal of blood from the arterial catheter and infusion of
the study solution into the venous catheter at a rate of 0.1 ml/
minute (33 pump; Harvard Apparatus, Hollister, MA, USA).
60% Blood volume exponential hemorrhage and shock
The animals were hemorrhaged (60% of BV) 10 minutes after
the completion of the hemodilution during a 1-hour period at a
rate of 0.3 ml/minute. Arterial blood was removed by a peristal-
tic pump (P720; Instech, Plymouth Meeting, PA, USA) con-
nected to the arterial line. The pump was started at the
beginning of each 10-minute period and run for a time calcu-
lated to complete removal of 60% of the blood volume by the
end of 1 hour. The total blood volume (TBV) at the end of each
10-minute period is as follows:
TBV = TBV0 × e-0.01526t
Where TBV0 is the initial blood volume (assumed to be 70 ml/
kg) and t is time (minutes). The amount of blood withdrawal
each time was determined from this algorithm [24], and there-
fore we drew progressively smaller amounts of blood during
the hour to simulate a surgical bleed. At the end of the 60-
minute hemorrhage period, the animals were monitored for an
additional 1-hour period of shock before they were killed
euthanasia. The animals were categorized as nonsurvivors and
killed earlier if at any time during the protocol their MAP fell
below 30 mmHg for more than 10 minutes.
Systemic and microvascular parameters were measured at
baseline and after hemodilution, hemorrhage and shock. MAP,
HR, and FCD were measured every 10 minutes during the
hemorrhage period after each blood withdrawal. Microvascu-
lar vessel diameter and blood flow were measured at 30-
minute intervals after the first hemorrhage (H30 and H60) and
continued in the shock phase (S30 and S60). Arterial blood
gases and hematocrit were measured at baseline, after
hemodilution, and the end of the shock period.
Study materials
Table 1 presents the physical properties of the study solutions
PEG-albumin and HES.
Polyethlyene surface decorated human serum albumin 
(PEG-albumin)
PEG-albumin is synthesized by extension arm facilitated
PEGylation protocol using lyophilized and essentially fatty acid
free, approximately 99% pure human serum albumin (HSA;
Sigma-Aldrich, Inc., MO, USA), 2-iminothiolane (lot #10222;
BioAffinity Systems, Inc. Rockford, IL, USA), and maleimide
phenyl PEG 5000 (lot #01186; BioAffinity Systems). Using
extension arm facilitated PEGylation, the HSA was surface
decorated with an average of six copies of PEG-5,000 [25].
Human serum albumin in phosphate-buffered saline (pH 7.4)
at a concentration of 32 mg/ml was incubated with 0.69 mg/
ml of 2-iminothiolane (10-fold molar excess over albumin) and
50 mg/ml maleimide phenyl PEG-5,000 (20-fold molar excess
over albumin) for an overnight reaction under cold conditions
(4°C). The ratio of HSA and iminothiolane was standardized
such that an average of six free thiols generated on the HSA,
which are estimated using the 4-PDS method (4,4'-dithiodipy-
ridine; Sigma-Aldrich, St. Louis, MO, USA) [26]. All of the
reaction components were mixed in a single step so that thiols
generated on the protein in situ are immediately modified byCritical Care    Vol 12 No 2    Martini et al.
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maleimide phenyl PEG-5,000. Excess iminothiolane and PEG
reagent present in the reaction mixture was removed by tan-
gential flow filtration through 50 kDa molecular weight cutoff
membranes against phosphate-buffered saline (pH 7.4) using
the Minim™ Tangential Flow Filtration instrument (Pall Corpo-
ration, Ann Arbor, MI, USA). After complete removal of
unbound PEG (established by size exclusion chromatography
and monitoring of the refractive index of the effluent) the reac-
tion mixture was concentrated to 40 mg/ml. PEGylated human
serum albumin sample was sterilized by filtering through 0.22
μ Millipore filters. The concentration of PEGylated HSA was
verified using the Bradford protein assay (Pierce Biotechnol-
ogy, Inc. Rockford, IL, USA). Measurement of colloidal oncotic
pressure at room temperature was about 42 mmHg and vis-
cosity 2.2 cP at 37°C for 4% solution. The number of PEG
chains on HSA molecule was analyzed by nuclear magnetic
resonance and mass spectroscopy, which has confirmed
attachment of an average of six copies PEG-5,000 chains per
HSA molecule. Based on SDS-PAGE, nuclear magnetic reso-
nance, and MALDI-TOF-MS (matrix assisted laser desorption
ionisation time-of-flight mass spectrometry), the average
molecular weight of this hexaPEGylated HSA is about 96 kDa.
High-performance liquid chromatography analysis showed the
product to have one broad peak with slight assymmetry. This
peak position corresponds to the HSA molecule with six PEG
chains, with a small contribution from HSA molecule with five
PEG chains. Hydrodynamic radius of the hexaPEGylated HSA
is at the range of 7.2 to 7.8 nm. The availability of the free thiols
on HSA after PEGylation was also estimated using the 4-PDS
method and is about 0.1 group per molecule. It is assumed
that the molecular radius of this product is around 7.5 nm, as
compared with 4 nm for the HSA.
Hydroxyethyl starch
HES of low molecular weight and with low degree of substitu-
tion (mean molecular weight 130 ± 20 kDa, degree of substi-
tution 0.4) was formulated at 6% (weight/vol) in 0.9% saline
injection (Voluven; Fresenius-Kabi) [27].
Statistical methods
One way analysis of variance was performed between time
points of interest within a treatment group, with Tukey post hoc
analysis when differences were found; this method that
accounts for the progressive decrease in number of observa-
tions resulting from loss of animals. Mann-Whitney test was
used to compare the two treatment group at time points of
interest. The product limit method (Kaplan-Meier) was used to
produce survival curves, and analysis of survival was con-
ducted using the log-rank test (Mantel-Cox). Statistical analy-
ses were performed with Prism 5.01 software (Graphpad, San
Diego, CA, USA). Results were considered statistically signif-
icantly different at P < 0.05. Data are presented as mean ±
standard deviation (with the exception of flow, which is pre-
sented as mean ± standard error of the mean).
Results
Ten animals were entered into the study and divided randomly
into two treatment groups before the experiment: PEG-albu-
min (n = 5) and HES (n = 5). Systemic data from baseline for
both groups were combined because there were no differ-
ences between groups.
Survival
Figure 1 shows the percentage survival during the experiment.
All animals in the PEG-albumin group survived the protocol
whereas none of the animals in the HES group completed the
hemorrhage phase of the experimental protocol. The differ-
ence in survival between PEG-albumin and HES was statisti-
cally significant (P = 0.003).
Systemic and laboratory parameters
MAP and HR during the experimental protocol after hemodilu-
tion (HD) and at H0, H30, H60, S30 and S60 are presented
in Table 2. These time points were chosen for comparison
because they represent the most significant events in this
experimental protocol: HD, hemodilution, H0 is immediately
after the first and most extreme hemorrhage; H30 is the mid-
point in the hemorrhage period, when most of the 60% volume
has been withdrawn; H60 is the end of the hemorrhage
Table 1
Properties of the study solutions
Property Hamster blood PEG-albumin HES
Concentration (%) - 4 6
Average molecular weight (kDa) 96 130
Suspending fluid - Phosphate buffer Saline
Viscosity (cp) 4.2 2.2 2.1
COP (mmHg) 16 42 42
Degree of substitution - - 0.40
Shown are the properties of the study solutions and of hamster blood. The concentrations of the fluids were chosen so that their viscosity and 
colloid osmotic pressures (COPs) were matched. To achieve a match of these parameters, the colloids were used at different concentrations. 
HES, hydroxyethyl starch; PEG-albumin, polyethylene glycol-conjugated human serum albumin.Available online http://ccforum.com/content/12/2/R54
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period/start of the shock period; S30 is 30 minutes into shock;
and S60 is the end of the experiment. Hemodilution did not
significantly change MAP and HR among groups relative to
baseline because the procedure was performed at a slow rate,
in order to allow the animals to compensate for the lowered
oxygen carrying capacity and changes in blood rheology.
Hemorrhage significantly reduced the MAP and HR in both
treatment groups, with PEG-albumin being able to maintain a
statistically higher MAP compared with HES until 30 minutes
into the hemorrhage.
Laboratory parameter changes are presented in Table 3. As
expected, hemodilution reduced hematocrit. The PEG-albumin
group had a hematocrit that was statistically lower than that in
the HES group. Lower PaO2 values were obtained for the
PEG-albumin versus HES. As expected, at the end of the hem-
orrhage phase and during the shock phase, there was a pro-
gressive increase in PaO2, and a decrease in PaCO2 and pH
(H60 to S60). The HES group did not compensate for hemor-
rhage and consequently had a reduced albeit positive acid-
base balance after hemodilution.
Microhemodynamics
Figures 2 and 3 present the changes in diameter and blood
flow for arterioles and venules during the experiment.
Arteriolar diameter and flow
Hemodilution with all solutions resulted in statistically signifi-
cant arteriolar vasodilation. The PEG-albumin group exhibited
a greater vasodilatory response than did the HES group. Dur-
ing the hemorrhage and shock phases, the dilated arterioles
for the PEG-albumin group vasoconstricted back to baseline
levels. This response by the PEG-albumin animals was main-
tained for the entire observation period and was statistically
different from that in HES animals. The HES animals exhibited
significant arteriolar vasoconstriction relative to baseline dur-
ing hemorrhage.
Arteriolar vasodilation after hemodilution with PEG-albumin
was concomitant with a significant increase in blood flow,
whereas the flow with HES remained unchanged from base-
line. After the initial hemorrhage step, both groups experi-
enced reduced blood flow relative to baseline and
hemodilution. At the H30 time point, the HES-treated group
had a statistically significant reduction in flow when compared
with the PEG-albumin group.
Venular diameter and flow
Hemodilution did not affect venular diameter, which remained
unchanged during the hemorrhage phase relative to baseline
in the PEG-albumin group. The HES group had venular vaso-
constriction, which was significant relative to baseline and
hemodilution, and the other study group at these time points.
After the exponential hemorrhage was completed and the ani-
mals continued into the shock phase (60% of the initial blood
volume was removed [H60]) the venular vessels vasocon-
stricted at all time points relative to baseline.
Blood flow was increased in the PEG-albumin group after
hemodilution but remained unchanged relative to baseline in
the HES group. At the H30 time point all animals in the HES
treatment group had pressures that categorized them as 'non-
survivors' and had essentially no microvascular perfusion.
Functional capillary density
Changes in FCD after hemodilution and during the hemor-
rhage phase of the experiment are shown in Figure 4. The FCD
data were evaluated at time points hemodilution, H0, H10,
H30 and H60, the other time points are shown to illustrate the
trend in the data. Hemodilution caused a significant fall in FCD
for the HES group, but the PEG-albumin group remained at
levels not different from baseline. Immediately after the largest
blood volume withdrawal (at H0), FCD was significantly
reduced relative to baseline and hemodilution. However, PEG-
albumin was able to sustain a higher FCD level relative to HES.
A similar pattern was observed at H10. FCD dropped as low
as 0.08 of baseline during later time points, a level that was
maintained during shock phase.
Discussion
The principal finding of this study is the notable difference in
outcome between using PEG-albumin and HES solutions in a
protocol designed to simulate a preoperative hemodilution fol-
lowed by significant surgical hemorrhage (exponential bleed of
60% BV). All PEG-albumin treated animals survived hemor-
rhage and completed the study, whereas HES-treated animals
did not even survive the hemorrhage period. A factor related to
the survival rates was the significantly higher FCD obtained
with the PEG-albumin group as compared with the other
group after the initial hemorrhage.
Figure 1
Percentage survival of the different treatment groups during the proto- col after the hemodilution Percentage survival of the different treatment groups during the proto-
col after the hemodilution. Treatment groups: polyethylene glycol-conju-
gated human serum albumin (PEG-albumin; solid black circles) and 
hydroxyethyl starch (HES; solid black triangles).Critical Care    Vol 12 No 2    Martini et al.
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Previous hemorrhagic shock studies conducted in our labora-
tory demonstrated the importance of maintaining tissue per-
fusion and demonstrated a strong correlation between FCD
and survival [28]. Local perfusion probably limits metabolite
accumulation during low flow states [13], and this may lead to
better outcomes [28].
Even though FCD was maintained in surviving animals during
the initial hemorrhage phase, it later dropped to levels as low
as 0.08 compared with baseline because of the severity of the
protocol.
The hematocrit differences between groups after hemodilution
could be indicative of differences in intravascular volume. Vol-
ume expansion beyond baseline blood volume after the
hemodilution would preload the animal with fluids and may
affect outcome. At the microvascular level, PEG-albumin
achieved higher blood flow and FCD in comparison with HES.
Because the period between hemodilution and initiation of
hemorrhage was 10 minutes, it is likely that only volume expan-
sion and not volume retention plays a role in outcome for this
study.
The hemodilution in the present study reduced the oxygen
reserve, as indicated by the decreases in systemic hematocrit
to 31.6% and 26.4% for HES and PEG-albumin, respectively.
In a resting animal, this hemodilution level corresponds to a
reduction in oxygen-carrying capacity that has been shown not
to affect oxygen delivery or tissue oxygenation [29]. In the HES
group, which exhibited greater oxygen-carrying capacity after
hemodilution as compared with the PEG-albumin group, the
PaO2 increased; this suggests a compensatory hyperventila-
tion response, which was not present with the PEG-albumin
group.
The effects of the suspending fluid of these solutions can also
influence outcome. The clinical relevance of hyperchloremic
acidosis is not fully understood and remains controversial [30].
Table 2
Mean arterial pressure and heart rate
PEG-albumin HES
MAP HR MAP HR
HD 96.6 ± 5.6 482.4 ± 28.8 100.0 ± 8.3 493.8 ± 20.9
H0 56.8 ± 7.2*†b 396.8 ± 65.0*† 43.0 ± 10.7*† 305.3 ± 83.5*†
H30 43.0 ± 7.6*†b 342.8 ± 54.0*† 33.3 ± 6.7*† 376.8 ± 98.8*†
H60 42.6 ± 10.3*† 367.2 ± 34.6*† --
S30 46.0 ± 10.2*† 338.2 ± 18.5*† --
S60 46.0 ± 11.9*† 325.8 ± 21.0*† --
Shown are the changes in MAP and HR between the two study groups at different time points. Baseline: MAP (mmHg) = 107.4 ± 8.2, HR (beats/
minute) = 466.3 ± 24.2. Within the same treatment group: *versus baseline; †versus hemodilution. Among treatments: PEG-albumin versus bHES. 
HD, hemodilution; H0, beginning of hemorrhage; H30, midpoint in the hemorrhage period when most of the 60% volume has been withdrawn; 
H60, end of the hemorrhage period; HES, hydroxyethyl starch; HR, heart rate; MAP, mean arterial pressure; PEG-albumin, polyethylene glycol-
conjugated human serum albumin; S30, 30 minutes after beginning of shock; S60, end of the experiment.
Table 3
Hemoglobin, hematocrit and arterial blood gases
Baseline HD H60 S60
PEG-albumin HES PEG-albumin HES PEG-albumin HES
Hematocrit (%) 46.4 ± 1.4 26.4 ± 0.9*b 31.6 ± 1.1* 18.2 ± 0.4*† - 18.1 ± 0.5*† -
PaO2 (mmHg) 58.9 ± 8.7 59.5 ± 11.3b 69.6 ± 7.0 100.0 ± 12.8*† - 121.0 ± 14.3*†‡ -
PaCO2 (mmHg) 59.1 ± 10.1 59.7 ± 5.0 51.1 ± 5.3 45.3 ± 12.9 - 36.1 ± 8.1*† -
pH arterial 7.388 ± 0.030 7.387 ± 0.036 7.349 ± 0.025 7.251 ± 0.076*† - 7.109 ± 0.047*†‡ -
BE (mmol/l) 5.5 ± 1.9 5.3 ± 2.3 1.8 ± 1.8* -8.2 ± 2.8*† - -18.0 ± 4.7*† -
Shown are changes in hemoglobin, hematocrit and arterial blood gases between the two study groups at different time points. Within the same 
treatment group: *versus baseline; †versus HD; ‡versus H60. Among treatments: PEG-albumin versus bHES. BE, base excess; HD, hemodilution; 
H60, end of the hemorrhage period; HES, hydroxyethyl starch; PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; PEG-
albumin, polyethylene glycol-conjugated human serum albumin; S60, end of the experiment.Available online http://ccforum.com/content/12/2/R54
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HES is suspended in saline, and when it is administered in
large volumes intravenously – as in the case of hemodilution –
this could lead to a nonphysiologic chloride load and meta-
bolic acidosis, as suggested by the observed disturbance in
acid-base balance. The HES group exhibited reduced pH and
base excess. Studies in both animals and humans show a rela-
tionship between electrolyte balanced and nonbalanced solu-
tions in terms of the extent of tissue perfusion [31,32].
Therefore PEG-albumin formulated in a phosphate buffer at a
physiological pH may perform better in terms of sustaining
flow and FCD.
Plasma expander viscosity has been shown to influence FCD
and local tissue perfusion during extreme hemodilution [33].
Increasing blood viscosity during hemodilution by using a
high-viscosity plasma expander (6% dextran 500 kDa, 0.7%
alginate) leads to better microvascular perfusion in compari-
son with using a low-viscosity plasma expander (6% dextran
70 kDa) [29,34,35]. The viscous drag exerted by plasma
expanders is proposed to interact with the endothelium and
trigger a vasodilator response. If the interaction is significantly
reduced, as in the case of low viscosity plasma expanders in
extreme hemodilution, then the production of vasodilators
such as nitric oxide by the endothelium is reduced)[36]. There-
fore, viscosity of the study fluids could influence the results
obtained after hemodilution. Studies of PEG-albumin in
extreme hemodilution have shown it to be effective at sustain-
ing high levels of microvascular perfusion, even though it is
only a moderately highly viscogenic fluid [11]. In the case of
PEG-albumin, the mechanism related to viscosity remains
unclear and it has been hypothesized that it may activate
endothelial pathways by direct physical interaction of the PEG
with the glycocalyx on the endothelium surface [37].
Nitric oxide plays a role in vascular regulation. Therefore the
ability of albumin to transport nitric oxide as S-nitrosothiols on
its surface could alter the vascular distribution of nitric oxide
and in turn regulate local blood flow [38]. PEGylation of albu-
min adds pseudo-thiols onto the protein surface, complement-
ing the number of natural thiols already available for nitric oxide
transport. This attribute of PEG-albumin may partially account
for its ability to maintain microvascular perfusion and FCD
above other colloids [11] without significantly increasing
Figure 2
Arteriolar and venular diameters Arteriolar and venular diameters. Changes to (a) arteriolar and (b) 
venular diameters at each time point of interest. Analysis within the 
same treatment group: *P < 0.05 relative to baseline; †P < 0.05 relative 
to HD, ‡P < 0.05 relative to H30. Analysis between treatments at the 
same time point (denoted by the
 horizontal bar): §P < 0.05. Data are expressed as mean ± standard 
deviation. HD, hemodilution; H0, beginning of hemorrhage; H30, mid-
point in the hemorrhage period when most of the 60% volume has 
been withdrawn; H60, end of the hemorrhage period; S30, 30 minutes 
after beginning of shock; S60, end of the experiment.
Figure 3
Arteriolar and venular blood flow Arteriolar and venular blood flow. Changes to (a) arteriolar and (b) 
venular blood flow at each time point of interest. Analysis within the 
same treatment group: *P < 0.05 relative to baseline; †P < 0.05 relative 
to HD, ‡P < 0.05 relative to H30. Analysis between treatments at the 
same time point (denoted by the horizontal bar): §P < 0.05. Data are 
presented mean ± standard error of the mean. HD, hemodilution; H0, 
beginning of hemorrhage; H30, midpoint in the hemorrhage period 
when most of the 60% volume has been withdrawn; H60, end of the 
hemorrhage period; S30, 30 minutes after beginning of shock; S60, 
end of the experiment.Critical Care    Vol 12 No 2    Martini et al.
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plasma viscosity above normal. During hemorrhage, RBC loss
reduces the nitric oxide scavenging potential of blood,
whereas ischemia induces nitric oxide synthase. Under these
conditions, the excess of nitric oxide in blood can be taken up
by PEG-albumin to be redistributed and then released in
hypoxic or acidic tissues. PEG-albumin has been shown to be
an effective resuscitation fluid compared with other colloidal
plasma expenders in various hemorrhagic shock scenarios
[13,39-41]. Although the major component of recovering local
perfusion from hemorrhagic shock is the ability of the plasma
expander to recover and sustain blood volume, a beneficial
effect of PEG-albumin could be related to the transport and
redistribution of nitric oxide, leading to improved local flow by
promoting vasodilation, reduced leukocyte adhesion and
platelet aggregation [42].
Conclusion
In the present study we tested the functionality of PEG-albu-
min used experimentally in preoperative hemodilution followed
by a significant surgical bleed. Survival time was longer with
PEG-albumin than with HES. PEG-albumin maintained capil-
lary perfusion during the initial stages of hemorrhage and was
able to re-establish functional capillaries at the end of hemor-
rhage. This effect cannot be accounted for by differences in
viscosities of both tested solutions, but it might be related to
the molecular structure of PEG-albumin. The chemical proc-
ess of PEGylation adds pseudo-thiols onto the surface of albu-
min, which increase its binding sites for nitric oxide. Nitric
oxide has been shown to be a very important transmitter that
regulates vasodilation and therefore influences local blood
flow. Our results could be interpreted as the effect of nitric
oxide redistribution by PEG-albumin, resulting in improved
flow and perfusion pressure to perfuse the capillary network. It
has been shown that the number of perfused capillaries is an
important predictor for survival from severe hemorrhagic shock
[28]. This underlines the importance of the ability of a resusci-
tation fluid to maintain capillary perfusion. In a setting of resus-
citation from severe hemorrhage, one might therefore
speculate that pre-hemodilution with PEG-albumin establishes
better resuscitation conditions compared with other colloid
solutions.
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